Clinical Pharmacology & Therapeutics
October 5, 2023
Robert H. Dworkin, Michael P McDermott, Sandeep M. Nayak et al.
16 citations
Clinical trials of psychedelics have provided support for their potential efficacy and safety.Although most combined a psychedelic with psychological support akin to psychotherapy, providing psychotherapy is costlier and more difficult to scale than providing only support to reduce harms.Trials with factorial designs can evaluate the individual effects of a psychedelic and psychotherapy and any...
Expert Opinion on Emerging Drugs
October 2, 2023
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek et al.
4 citations
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to...
Pharmacological Reports
October 1, 2023
Priscila Vázquez-león, Abraham Miranda-Páez, Hugo Sánchez-Castillo et al.
Periaqueductal gray matter (PAG) is a brain region rich in kappa-opioid receptors (KOR). KOR in PAG mediates behavioral responses related to pain integration, and panic response, among others. Its participation in the addiction phenomena has been poorly studied. Hence, this preliminary study explored the pharmacological effects of KOR stimulation/blockade in dorsal-PAG (D-PAG) during alcohol...
Journal of the Endocrine Society
October 1, 2023
Cihan Atila, Friederike Holze, Rakithan Murugesu et al.
Abstract Disclosure: C. Atila: None. F. Holze: None. R. Murugesu: None. N. Rommers: None. N. Hutter: None. N. Varghese: None. C.O. Sailer: None. A. Eckert: None. M. Heinrichs: None. M. Liechti: None. M. Christ-crain: None. Introduction: Despite adequate treatment, patients with arginine vasopressin deficiency (AVP-D), known as central diabetes insipidus (cDI), often report psychological...
Neuroscience & Biobehavioral Reviews
October 1, 2023
Omer A. Syed, Benjamin Tsang, Robert Gerlai
7 citations
In this review, we discuss the possible utility of zebrafish in research on psilocybin, a psychedelic drug whose recreational use as well as possible clinical application are gaining increasing interest. First, we review behavioral tests with zebrafish, focussing on anxiety and social behavior, which have particular relevance in the context of psilocybin research. Next, we briefly consider...
Scientific Reports
September 30, 2023
Alexander V. Lebedev, Kasim Acar, Otilia Horntvedt et al.
9 citations
Previous research has suggested that classical psychedelics can foster significant and enduring changes in personality traits and subjective wellbeing. Despite the lack of evidence for adverse effects on mental health stemming from psychedelic use, concerns persist regarding the capacity of these substances to modulate information processing and attitudes towards factual data. The aim of the...
Journal of Humanistic Psychology
September 22, 2023
Mitch Earleywine, Maha N. Mian, Joseph A. de Leo
5 citations
Expectancy effects for many psychoactive substances appear to play a role in consumption, problematic use, subjective responses to acute administration, and subsequent effects. Expectancies of psychedelics have received little attention in published research despite their reputation for creating dramatic changes in subjective state. Psilocybin-assisted treatment (PAT) improves depression, but...
Frontiers in Psychiatry
September 19, 2023
Hillary Jackson, Sara So, Abigail Yaffe et al.
87 citations
Introduction The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials. Naturalistic use of psilocybin outside of research settings has increased in recent years, though data on the public health impact of such use remain limited. Methods This prospective, longitudinal...
Frontiers in Psychiatry
September 18, 2023
Karina Sergi, Micah Linton, Rhianna Rich et al.
21 citations
Introduction Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2 trials for alcohol use disorder (AUD). Set and setting, particularly factors facilitating a connection with nature, may positively influence the psychedelic experience and therapeutic outcomes. But to date, randomized controlled trials of interventions to enhance set and setting for psychedelic-assisted...
Biological Psychiatry
September 15, 2023
Robin J Murphy, Rachael Sumner, William Evans et al.
69 citations
Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity. Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups...